Phathom Pharmaceuticals (PHAT) clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later on August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of any Frazier fund or person in Phathom. While the breakout of holdings between funds and persons may appear different than prior filings, and the treatment of warrants may reduce certain percentages in the updated filings, these differences are due solely to clarifying changes in Frazier’s reporting approach and not to any sale of shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Phathom Pharmaceuticals Reports Strong Q2 Growth
- Phathom Pharmaceuticals: Strong Buy Rating Driven by Robust Revenue Performance and Growth Potential
- Phathom Pharmaceuticals reports Q2 EPS (79c), consensus (89c)
- Phathom Pharmaceuticals sees 2025 revenue $165M-$175M, consensus $159.4M